Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 2, 2006, Pages 265-272

  Gerra, Gilberto ^a,e   Leonardi, Claudio ^b   D'Amore, Antonio ^c   Strepparola, Giovanni ^d   Fagetti, Roberto ^b   Assi, Cinzia ^d   Zaimovic, Amir ^a   Lucchini, Alfio ^d  

^a AUSL   (Italy)

^b ASL Roma B   (Italy)

^c Department of Diagnostic Imaging   (Italy)

^d ASL of Milan   (Italy)

^e Dipartimento Nazionale Politiche Antidroga   (Italy)

Author keywords

Anxiety; Buprenorphine; Dual diagnosis treatment; Heroin; Major depression; Personality disorder; Schizophrenia; Substance use disorder

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; ILLICIT DRUG; KAPPA OPIATE RECEPTOR ANTAGONIST; METHADONE; NALTREXONE;

ABSTINENCE; ADULT; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEFENSE MECHANISM; DRUG EFFICACY; DRUG MEGADOSE; DYSPHORIA; FACTORIAL ANALYSIS; FEMALE; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PERSONALITY DISORDER; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME; URINALYSIS;

ADULT; ANXIETY; BUPRENORPHINE; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NARCOTICS; PERSONALITY DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 33344456188     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.10.007     Document Type: Article

References (37)

1. P.G. Barnett, J.H. Rodgers, and D.A. Bloch A meta-analysis comparing buprenorphine to METH for treatment of opiate dependence 672 Addiction 96 5 2001 683 690
2. J.A. Bodkin, G.L. Zornberg, S.E. Lukas, and J.O. Cole Buprenorphine treatment of refractory depression J. Clin. Psychopharmacol. 15 1 1995 67549 67557
3. A.E. Calogero, S. Scaccianoce, N. Burrello, R. Nicolai, L.A. Muscolo, M.A. Kling, L. Angelucci, and R. D'Agata The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro J. Neuroendocrinol. 8 8 1996 579 585
4. S.D. Comer, E.D. Collins, and M.W. Fischman Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans Psychopharmacology (Berl.) 154 1 2001 28 37
5. K.P. Conway, R.J. Kane, S.A. Ball, J.C. Poling, and B.J. Rounsaville Personality, substance of choice, and polysubstance involvement among substance dependent patients Drug Alcohol Depend. 71 1 2003 65 75
6. A.J. Dean, J. Bell, M.J. Christie, and R.P. Mattick Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence Eur. Psychiatr. 19 8 2004 510 513
7. Diagnostic and Statistical Manual of Mental Disorders Fourth edition (DSM-IV) 1994 American Psychiatric Association Washington, DC
8. H.M. Emrich, R. Gunther, and M. Dose Current perspectives in the pharmacopsychiatry of depression and mania Neuropharmacology 22 3 Spec No 1983 385 388
9. M. Fava, G.B. Guaraldi, F. Mazzi, and M. Rigatelli Intervista Clinica Strutturata per il DSM-III-R 1993 Organizzazioni Speciali Florence
10. G. Fischer, W. Gombas, H. Eder, R. Jagsch, A. Peternell, G. Stuhlinger, L. Pezawas, H.N. Aschauer, and S. Kasper Buprenorphin versus METH maintenance for the treatment of opioid dependence Addiction 94 9 1999 1337 1347
11. G. Fischer, W. Gombas, H. Eder, R. Jagsch, G. Stuhlinger, H.N. Aschauer, and S. Kasper Buprenorphine vs. METH as maintenance treatment for opioid dependence Nervenarzt 70 9 1999 795 802
12. G. Gerra, F. Borella, A. Zaimovic, G. Moi, M. Bussandri, C. Bubici, and S. Bertacca Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome Drug Alcohol Depend. 75 1 2004 37 45
13. M.K. Greenwald, and M.L. Stitzer Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine Drug Alcohol Depend. 53 1 1998 17 30
14. T.R. Kosten, C. Morgan, and T.A. Kosten Depressive symptoms during buprenorphine treatment of opioid abusers J. Subst. Abuse Treat. 7 1 1990 51 54 (724)
15. T. Kosten, J. Falcioni, A. Oliveto, and A. Feingold Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone Am. J. Addict. 13 2 2004 191 201
16. M.R. Levenson, K.A. Kiehl, and C.M. Fitzpatrick Assessing psychopathic attributes in a noninstitutionalized population J. Pers. Soc. Psychol. 68 1 1995 151 158
17. D.J. Kupfer Pathophysiology and management of insomnia during depression Ann. Clin. Psychiatry 11 4 1999 267 276
18. C. Maffei, A. Fossati, I. Agostani, A. Barraco, M. Bagnato, D. Donati, C. Namia, L. Novella, and M. Petrachi Interrater reliability and internal consistency of the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II), Version 2.0 J. Pers. Disord. 11 1997 279 284
19. R.P. Mattick, J. Kimber, C. Breen, and M. Davoli Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database Syst. Rev. 2 2003 CD002207
20. P.P. Pani, I. Maremmani, R. Pirastu, A. Tagliamonte, and G.L. Gessa Buprenorphine: a controlled clinical trial in the treatment of opioid dependence Drug Alcohol Depend. 60 1 2000 39 50
21. D. Peckys, and Y.L. Hurd Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders Brain Res. Bull. 55 5 2001 619 624
22. B. Pfohl, N. Blum, M. Zimmerman, and D. Stangl Structured Interview for Personality Disorders, Revised Version 1989 University of Iowa 752 Iowa City, IA
23. W.B. Pickworth, R.E. Johnson, B.A. Holicky, and E.J. Cone Subjective and physiologic effects of intravenous buprenorphine in humans Clin. Pharmacol. Ther. 53 5 1993 570 576
24. M.F. Poirier, X. Laqueille, V. Jalfre, D. Willard, M.C. Bourdel, J. Fermanian, and J.P. Olie Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 2 2004 267 272
25. U. Rao, N.D. Ryan, R.E. Dahl, B. Birmaher, R. Rao, D.E. Williamson, and J.M. Perel Factors associated with the development of substance use disorder in depressed adolescents J. Am. Acad. Child Adolesc. Psych. 38 1999 1109 1117
26. R.B. Rothman A review of the role of anti-opioid peptides in morphine tolerance and dependence Synapse 12 2 1992 129 138
27. R.B. Rothman, J.B. Long, V. Bykov, H. Xu, A.E. Jacobson, K.C. Rice, and J.W. Holaday Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence Peptides 12 1 1991 151 160
28. R.B. Rothman, D.A. Gorelick, S.J. Heishman, P.R. Eichmiller, B.H. Hill, J. Norbeck, and J.G. Liberto An Open-Label Study of a Functional Opioid Kappa Antagonist in the Treatment of Opioid Dependence 2000
29. R.S. Schottenfeld, J.R. Pakes, and T.R. Kosten Prognostic factors in Buprenorphine- versus METH-maintained patients J. Nerv. Ment. Dis. 186 1 1998 35 43
30. T.S. Shippenberg, V.I. Chefer, A. Zapata, and C.A. Heidbreder Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems Ann. N.Y. Acad. Sci. 937 2001 50 73
31. C.M. Sonnenberg, A.T. Beekman, D.J. Deeg, and V. an Tilburg Drug treatment in depressed elderly in the Dutch community Int. J. Geriatr. Psychiatry 18 2 2003 99 104
32. R.L. Spitzer, J.B.W. Williams, M. Gibbon, and M.B. First Structured Clinical Interview According to DSM-III-R 1990 American Psychiatric Press Washington, DC
33. M. Ukai, M. Suzuki, and T. Mamiya Effects of U-50,488H, a kappa-opioid receptor agonist, on the learned helplessness model of depression in mice J. Neural Transm. 109 9 2002 1221 1225
34. A. Umbricht, M.A. Huestis, E.J. Cone, and K.L. Preston Effects of high-dose intravenous buprenorphine in experienced opioid abusers J. Clin. Psychopharmacol. 24 5 2004 479 487
35. M. Valenstein, K.K. Taylor, K. Austin, H.C. Kales, J.F. McCarthy, and F.C. Blow Benzodiazepine use among depressed patients treated in mental health settings Am. J. Psychiatry 161 4 2004 654 661
36. P. Voyer, P. Landreville, J. Moisan, M. Tousignant, and M. Preville Insomnia, depression and anxiety disorders and their association with benzodiazepine drug use among the community-dwelling elderly: implications for mental health nursing Int. J. Psychiatr. Nurs. Res. 10 2 2005 1093 1116
37. S.L. Walsh, E.C. Strain, M.E. Abreu, and G.E. Bigelow Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans Psychopharmacology (Berl.) 157 2 2001 151 162